Physician profile
Joseph D'Amore
NPI 1932193513
$6,886.64
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $464 · 2021: $1,252 · 2022: $946 · 2023: $1,962 · 2024: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,000.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,609.77 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $979.81 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $967.64 | 2021-2024 | |
| Optinose US, INC. | $390.20 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.19 | 2019-2020 | |
| Pfizer INC. | $214.16 | 2022 | |
| Amgen INC. | $169.99 | 2019-2021 | |
| Lilly USA, LLC | $94.59 | 2019-2022 | |
| Genentech USA, INC. | $73.60 | 2021-2024 | Xolair |
| Janssen Biotech, INC. | $52.93 | 2019-2020 | |
| Viiv Healthcare Company | $38.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph D'Amore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.